In 1991, the John Wayne Cancer Institute (JWCI) launched a successful affiliation with Saint John’s Health Center and opened in Santa Monica, California. Combined with the exceptional quality of Saint John’s medical staff and hospital, a unique community-based cancer research and training institute was formed, outstanding in the areas of translational research and the treatment of solid tumors including surgical oncology, immunotherapy, chemotherapy, and radiation.
Leading this remarkable charge was the late Donald L. Morton, M.D., a larger than life presence who was born in a rural, coal-mining town in West Virginia. His persistent, scientific questioning of the role of the immune system in fighting cancer led to many advances throughout his decorated career.
Donald Morton, M.D., advancements include:
- Development of the sentinel lymph node biopsy technique for melanoma and breast
- First successful use of immunotherapy in human malignancy
- Received one of the largest National Cancer Institute grants awarded to a single clinical cancer study (26.8 million five-year grant)
- Designed and ran two international, multicenter landmark surgical trials, MSLT –I and MSLT – II
- Authored over 1,000 publications
- Trained over 150 surgical oncologists
Announcing Steven O’Day, MD, as the new Executive Director of the John Wayne Cancer Institute & Director of Providence Los Angeles Regional Research
Dr. O’Day is a true leader, but first he is a brilliant physician whose groundbreaking research has saved lives.
Recognized throughout the world for surgical excellence, the John Wayne Cancer Institute attracts some of the most talented researchers and physicians that provide personalized patient care.
Learn more about our nationally ranked team of cancer experts today by visiting their bios.Directory
Landmark Articles Published by JWCI Faculty
Sentinel Lymph Node Biopsy Technique in Melanoma “Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma.” Archives of Surgery
Use of SLN in Breast Cancer “Lymphatic Mapping and Sentinel Lymphadenectomy for Breast-Cancer” Annals of Surgery
Multicenter Selective Lymphadenectomy Trial-I (MSLT-I) – “Sentinel-Node Biopsy or Nodal Observation in Melanoma” NEJM
Immunotherapy in Metastatic Melanoma “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma“. NEJM
Now the John Wayne Cancer Institute has expanded its fight against cancer to many different diseases, including urologic, thoracic, endocrine, gynecologic, and neurologic cancers. The translational research, surgical, and oncologic teams have quadrupled over the past three years as we continue to fight the battle with cancer.
Fundamental, innovative research on the biology of cancer at the John Wayne Cancer Institute provides the foundation of knowledge on which treatment and cures are built, here and at institutions worldwide. The Institute is home to bold collaborative research initiatives as well as a strong commitment to training and mentoring the next generation of cancer scientists and surgeons.
RESEARCH + CLINICAL CARE = BENCH-TO-BEDSIDE MEDICINE
The Institute benefits from continuous interaction between its world renowned researchers and physicians who are involved in day-to-day diagnosis and treatment of patients with a wide variety of cancers. The distance from bench to bedside is only a few steps at the Institute.
The Institute serves cancer research and treatment worldwide through its unique tissue bank and accompanying database, as well as the Surgical Oncology Fellowship Program.